• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖流行对高血压和肾脏疾病的影响。

Impact of the obesity epidemic on hypertension and renal disease.

作者信息

Hall John E, Jones Daniel W, Kuo Jay J, da Silva Alexandre, Tallam Lakshmi S, Liu Jiankang

机构信息

Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA.

出版信息

Curr Hypertens Rep. 2003 Oct;5(5):386-92. doi: 10.1007/s11906-003-0084-z.

DOI:10.1007/s11906-003-0084-z
PMID:12948431
Abstract

Excess weight gain is a major cause of increased blood pressure in most patients with essential hypertension, and also greatly increases the risk for renal disease. Obesity raises blood pressure by increasing renal tubular reabsorption, impairing pressure natriuresis, causing volume expansion due to activation of the sympathetic nervous system and renin-angiotensin system, and by physical compression of the kidneys, especially when visceral obesity is present. The mechanisms of sympathetic nervous system activation in obesity may be due, in part, to hyperleptinemia that stimulates the hypothalamic pro-opiomelanocortin pathway. With prolonged obesity, there may be a gradual loss of nephron function that worsens with time and exacerbates hypertension. Weight reduction is an essential first step in the management of obesity hypertension and renal disease. Special considerations for the obese patient, in addition to adequately controlling the blood pressure, include correction of the metabolic abnormalities and protection of the kidneys from further injury.

摘要

体重过度增加是大多数原发性高血压患者血压升高的主要原因,也会大大增加患肾病的风险。肥胖通过增加肾小管重吸收、损害压力性利钠作用、因交感神经系统和肾素-血管紧张素系统激活导致血容量扩张以及对肾脏的物理压迫(尤其是存在内脏肥胖时)来升高血压。肥胖中交感神经系统激活的机制可能部分归因于刺激下丘脑阿片促黑激素皮质素原途径的高瘦素血症。随着肥胖时间延长,可能会逐渐出现肾单位功能丧失,且会随着时间恶化并加重高血压。减轻体重是肥胖相关性高血压和肾病管理的关键第一步。对于肥胖患者,除了充分控制血压外,特殊考虑因素还包括纠正代谢异常以及保护肾脏免受进一步损伤。

相似文献

1
Impact of the obesity epidemic on hypertension and renal disease.肥胖流行对高血压和肾脏疾病的影响。
Curr Hypertens Rep. 2003 Oct;5(5):386-92. doi: 10.1007/s11906-003-0084-z.
2
Pathophysiology and treatment of obesity hypertension.肥胖相关性高血压的病理生理学与治疗
Curr Pharm Des. 2004;10(29):3621-37. doi: 10.2174/1381612043382855.
3
Is obesity a major cause of chronic kidney disease?肥胖是慢性肾病的主要病因吗?
Adv Ren Replace Ther. 2004 Jan;11(1):41-54. doi: 10.1053/j.arrt.2003.10.007.
4
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.肥胖诱导的高血压:神经体液机制与肾脏机制的相互作用
Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.
5
Obesity-associated hypertension and kidney disease.肥胖相关的高血压和肾脏疾病。
Curr Opin Nephrol Hypertens. 2003 Mar;12(2):195-200. doi: 10.1097/00041552-200303000-00011.
6
Pathophysiology of obesity hypertension.肥胖相关性高血压的病理生理学
Curr Hypertens Rep. 2000 Apr;2(2):139-47. doi: 10.1007/s11906-000-0073-4.
7
The role of the sympathetic nervous system in obesity-related hypertension.交感神经系统在肥胖相关高血压中的作用。
Curr Hypertens Rep. 2009 Jun;11(3):206-11. doi: 10.1007/s11906-009-0036-3.
8
Factors that influence the risk of hypertension in obese individuals.影响肥胖个体患高血压风险的因素。
Curr Opin Nephrol Hypertens. 2003 May;12(3):305-8. doi: 10.1097/00041552-200305000-00013.
9
Obesity, kidney dysfunction, and inflammation: interactions in hypertension.肥胖、肾功能障碍和炎症:高血压中的相互作用。
Cardiovasc Res. 2021 Jul 7;117(8):1859-1876. doi: 10.1093/cvr/cvaa336.
10
Mechanisms of hypertension and kidney disease in obesity.肥胖症中高血压和肾脏疾病的机制。
Ann N Y Acad Sci. 1999 Nov 18;892:91-107. doi: 10.1111/j.1749-6632.1999.tb07788.x.

引用本文的文献

1
Electrolyte Imbalances and Metabolic Emergencies in Obesity: Mechanisms and Clinical Implications.肥胖中的电解质失衡与代谢急症:机制与临床意义
Diseases. 2025 Feb 24;13(3):69. doi: 10.3390/diseases13030069.
2
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes.2型糖尿病患者肾脏疾病治疗的支柱
Pharmaceutics. 2023 Apr 27;15(5):1343. doi: 10.3390/pharmaceutics15051343.
3
Soluble (Pro)Renin Receptor in Hypertension.可溶性(前)肾素受体与高血压。

本文引用的文献

1
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.降压降脂预防心脏病发作试验(ALLHAT):实际意义。
Hypertension. 2003 May;41(5):1006-9. doi: 10.1161/01.HYP.0000070905.09395.F6. Epub 2003 Apr 14.
2
Interactions between leptin and the human sympathetic nervous system.瘦素与人体交感神经系统之间的相互作用。
Hypertension. 2003 May;41(5):1072-9. doi: 10.1161/01.HYP.0000066289.17754.49. Epub 2003 Mar 31.
3
Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function.
Nephron. 2023;147(3-4):234-243. doi: 10.1159/000525635. Epub 2022 Jul 22.
4
Development and Validation of a Nomogram-Based Prognostic Model to Predict High Blood Pressure in Children and Adolescents-Findings From 342,736 Individuals in China.基于列线图的预测儿童和青少年高血压的预后模型的开发与验证——来自中国342,736人的研究结果
Front Cardiovasc Med. 2022 Jun 23;9:884508. doi: 10.3389/fcvm.2022.884508. eCollection 2022.
5
The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure.脂肪细胞钠钾肽在逆转肥胖和新冠病毒感染所致全身炎症以预防心力衰竭发生中的关键作用
Antioxidants (Basel). 2020 Nov 14;9(11):1129. doi: 10.3390/antiox9111129.
6
Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study.高血压患者血脂谱和血液学参数的评估:基于实验室的横断面研究。
SAGE Open Med. 2018 Feb 12;6:2050312118756663. doi: 10.1177/2050312118756663. eCollection 2018.
7
Synergistical action of the β2 adrenoceptor and fatty acid binding protein 2 polymorphisms on the loss of glomerular filtration rate in Chinese patients with type 2 diabetic nephropathy.β2肾上腺素能受体与脂肪酸结合蛋白2基因多态性对中国2型糖尿病肾病患者肾小球滤过率降低的协同作用。
Int Urol Nephrol. 2018 Apr;50(4):715-723. doi: 10.1007/s11255-018-1812-2. Epub 2018 Feb 5.
8
Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis.2型糖尿病中心血管危险因素的血糖变异性:一项荟萃分析。
J Diabetes Metab Disord. 2017 Nov 14;16:45. doi: 10.1186/s40200-017-0323-5. eCollection 2017.
9
The Intricate Network of Adipokines and Stroke.脂肪因子与中风的复杂网络
Int J Endocrinol. 2015;2015:967698. doi: 10.1155/2015/967698. Epub 2015 Dec 10.
10
Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats.血管紧张素AT2受体激动剂可预防肥胖Zucker大鼠的盐敏感性高血压。
Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1379-85. doi: 10.1152/ajprenal.00002.2015. Epub 2015 Apr 8.
下丘脑黑素皮质素受体与动脉血压和肾功能的慢性调节
Hypertension. 2003 Mar;41(3 Pt 2):768-74. doi: 10.1161/01.HYP.0000048194.97428.1A. Epub 2002 Dec 30.
4
The kidney, hypertension, and obesity.肾脏、高血压与肥胖
Hypertension. 2003 Mar;41(3 Pt 2):625-33. doi: 10.1161/01.HYP.0000052314.95497.78. Epub 2003 Jan 20.
5
Obesity-associated hypertension and kidney disease.肥胖相关的高血压和肾脏疾病。
Curr Opin Nephrol Hypertens. 2003 Mar;12(2):195-200. doi: 10.1097/00041552-200303000-00011.
6
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies.体重减轻对超重慢性蛋白尿性肾病患者的有益影响。
Am J Kidney Dis. 2003 Feb;41(2):319-27. doi: 10.1053/ajkd.2003.50039.
7
Sympathetic neural activation in visceral obesity.内脏肥胖中的交感神经激活。
Circulation. 2002 Nov 12;106(20):2533-6. doi: 10.1161/01.cir.0000041244.79165.25.
8
Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT).饮食、运动与减肥干预试验(DEW-IT)的结果
Hypertension. 2002 Nov;40(5):612-8. doi: 10.1161/01.hyp.0000037217.96002.8e.
9
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.血管紧张素阻断通过脂肪细胞的形成预防2型糖尿病。
Hypertension. 2002 Nov;40(5):609-11. doi: 10.1161/01.hyp.0000036448.44066.53.
10
Prevalence and trends in overweight among US children and adolescents, 1999-2000.1999 - 2000年美国儿童及青少年超重的患病率及趋势
JAMA. 2002 Oct 9;288(14):1728-32. doi: 10.1001/jama.288.14.1728.